A novel GIP-oxyntomodulin hybrid peptide acting through GIP, glucagon and GLP-1 receptors exhibits weight reducing and anti-diabetic properties

A new glucagon and GLP-1 co-agonist eliminates obesity in rodents

Jonathan W. Day, Nickki Ottaway, James T Patterson et al. · Nature Chemical Biology · 2009 · 634 citations · Full text

Life Sciences, Endocrinology, Pharmacology +14

Cloning and Functional Expression of the Human Islet GLP-1 Receptor: Demonstration That Exendin-4 Is an Agonist and Exendin-(9–39) an Antagonist of the Receptor

Bernard Thorens, Andrée Porret, Léo H. Bühler et al. · Diabetes · 1993 · 540 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17

Oxyntomodulin Suppresses Appetite and Reduces Food Intake in Humans

Mark A. Cohen, Carel W. le Roux, Rachel L. Batterham et al. · The Journal of Clinical Endocrinology & Metabolism · 2003 · 473 citations · Full text

Medicine, Nutritional Sciences, Pharmacology +7

Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice

Peter R. Flatt, Clifford J. Bailey · Diabetologia · 1981 · 407 citations · Full text

Medicine, Endocrinology, Physiology +16

Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice

Alessandro Pocai, Paul E. Carrington, Jennifer R. Adams et al. · Diabetes · 2009 · 407 citations · Full text

Life Sciences, Endocrinology, Pharmacology +17